Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT01896583 is registered in ClinicalTrials.gov with Seldar Pharma, Inc. as lead sponsor.

NCT NCT01896583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Lead sponsor
Seldar Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
July 31, 2014
Enrollment
64 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea predominant irritable bowel syndrome